These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17802710)

  • 21. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2011 Jan; 9(101):1-6; quiz 2 p following 6. PubMed ID: 21304446
    [No Abstract]   [Full Text] [Related]  

  • 22. Hyponatraemia due to amantadine hydrochloride and L-dopa/carbidopa.
    Lammers GJ; Roos RA
    Lancet; 1993 Aug; 342(8868):439. PubMed ID: 8101938
    [No Abstract]   [Full Text] [Related]  

  • 23. [Parkinson's disease].
    Masson C
    Presse Med; 2001 Mar; 30(8):386-8. PubMed ID: 11268898
    [No Abstract]   [Full Text] [Related]  

  • 24. Melanoma and levodopa.
    Rampen F
    J Am Acad Dermatol; 1998 May; 38(5 Pt 1):782-4. PubMed ID: 9591833
    [No Abstract]   [Full Text] [Related]  

  • 25. Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone.
    Graham DJ; Williams JR; Hsueh YH; Calia K; Levenson M; Pinheiro SP; Macurdy TE; Shih D; Worrall C; Kelman JA
    Mov Disord; 2013 Apr; 28(4):490-7. PubMed ID: 23443994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Toxic and adverse neurological effects of anti-parkinsonian drugs].
    Sunohara N
    Ryoikibetsu Shokogun Shirizu; 1999; (27 Pt 2):527-31. PubMed ID: 10434715
    [No Abstract]   [Full Text] [Related]  

  • 27. Entacapone: prostate cancer?
    Prescrire Int; 2010 Oct; 19(109):217. PubMed ID: 21188808
    [No Abstract]   [Full Text] [Related]  

  • 28. Fracture risk associated with parkinsonism and anti-Parkinson drugs.
    Vestergaard P; Rejnmark L; Mosekilde L
    Calcif Tissue Int; 2007 Sep; 81(3):153-61. PubMed ID: 17705047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prevention and treatment of fluctuations in patients with Parkinson's disease].
    Ludin HP; Surber Ch
    Praxis (Bern 1994); 2006 Dec; 95(51-52):2013-8. PubMed ID: 17294589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Dopaminergic agonists in the treatment of Parkinson's disease].
    Supiot F; Sternon J; Zegers de Beyl D
    Rev Med Brux; 2000 Dec; 21(6):493-9. PubMed ID: 11194495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [78-year-old patient with urine discoloration].
    Krause O; Griebel LF; Heck J
    Dtsch Med Wochenschr; 2022 Jan; 147(1-02):15-16. PubMed ID: 34963169
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of levodopa-induced motor complications.
    Stocchi F; Tagliati M; Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Entocapone-related lymphocytic colitis].
    Maroy B
    Gastroenterol Clin Biol; 2008; 32(8-9):695-7. PubMed ID: 18436401
    [No Abstract]   [Full Text] [Related]  

  • 34. Adverse reactions to controlled release levodopa/carbidopa in older persons: case reports.
    Joseph CL; Siple J; McWhorter K; Camicioli R
    J Am Geriatr Soc; 1995 Jan; 43(1):47-50. PubMed ID: 7806739
    [No Abstract]   [Full Text] [Related]  

  • 35. [Pharmacological treatment of parkinsonism].
    Friedman A
    Neurol Neurochir Pol; 1977; 11(6):689-93. PubMed ID: 600352
    [No Abstract]   [Full Text] [Related]  

  • 36. [Various kinds of antiparkinson agents and their characteristics].
    Nakatsuka A; Nomoto M
    Nihon Naika Gakkai Zasshi; 2003 Aug; 92(8):1419-25. PubMed ID: 13677889
    [No Abstract]   [Full Text] [Related]  

  • 37. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.
    Caslake R; Macleod A; Ives N; Stowe R; Counsell C
    Cochrane Database Syst Rev; 2009 Oct; (4):CD006661. PubMed ID: 19821381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
    Kaakkola S
    Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Agonists versus levodopa in PD: the thrilla of whitha.
    Montgomery EB
    Neurology; 2003 Nov; 61(10):1462; author reply 1462-3. PubMed ID: 14638991
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease.
    Joutsa J; Martikainen K; Vahlberg T; Kaasinen V
    Parkinsonism Relat Disord; 2012 Dec; 18(10):1079-83. PubMed ID: 22784693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.